Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PTKFF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PTKFF and 80,000+ other tickers.
See exactly how PTKFF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTKFF and 80,000+ other tickers.
Indonesia-based pharmaceutical powerhouse, PT Kalbe Farma Tbk., along with its affiliated companies, is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products throughout the country. The organization structures its operations across four primary business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers a diverse range of medications, including generic, branded, and licensed drugs such as Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and…
No recent news available.